Pep IQ
← Pep IQ
Substantial preclinical and translational foundation. Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland, with a well-characterised molecular structure and mechanism. Mechanism: Toll-like receptor (TLR) signalling — primarily TLR9 and TLR2/4 — activating dendritic cells, NK cells, and T-cell maturation pathways. Upregulates surface expression of CD3, CD4, CD8 on existing T cells. Activates the indoleamine 2,3-dioxygenase enzyme that confers immune tolerance during transplantation while restraining chronic inflammation. The mechanism is genuinely pleiotropic — Romani et al. described Tα1 as 'jack of all trades' in Annals of the New York Academy of Sciences.
Standard community protocols converge on 1.0–1.5 mg SubQ twice weekly for 4–8 weeks for general immune support; the approved chronic hepatitis B protocol is 1.6 mg twice weekly for 26–52 weeks. Cancer adjuvant protocols use 1.6 mg biw for 6 months or between chemotherapy cycles. Compounded versions sourced through US compounding pharmacies operating under FDA sections 503A or 503B. Verify compounding pharmacy holds appropriate accreditation (e.g., PCAB) and conducts third-party potency and sterility testing — quality varies. Often combined with thymosin beta-4 (different mechanism — immune vs repair) in integrative protocols, though the stacking evidence is anecdotal rather than trial-validated.
Substantial clinical evidence base — among the most extensive of any research peptide. Chien et al. 2006 meta-analysis pooled multiple Phase 3 hepatitis B RCTs demonstrating significant sustained virological response with Tα1 monotherapy. NCT04428008 — Phase 2 prevention trial in renal dialysis patients during COVID-19. NCT01031966 (Sigma-Tau, Pubmed 22178096) — Phase 2 vaccine adjuvant trial showed Tα1 (3.2 and 6.4 mg) enhanced immunogenicity of pandemic H1N1 influenza vaccine in haemodialysis patients. Cancer adjuvant trials in over 1,000 patients (NSCLC, melanoma, hepatocellular, breast, NHL, colorectal, head/neck, leukaemia, pancreatic, renal cell) demonstrated improved immunological parameters, tumour response rates, survival, and quality of life. 2020 review (PMC 7747025) summarised the literature comprehensively.
Approved in 35+ countries as Zadaxin (thymalfasin) — primarily across Asia, South America, and parts of Europe — for chronic hepatitis B, chronic hepatitis C (combination therapy), and as immunotherapy adjuvant. Manufactured by SciClone Pharmaceuticals. Not FDA-approved; in the United States, accessed via compounding pharmacies. Held FDA orphan-drug designation for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly, and hepatocellular carcinoma. Animal safety: no adverse reactions in single doses up to 20 mg/kg or repeated 6 mg/kg/day for 13 weeks (highest doses tested). Human safety: no adverse reactions at doses up to 16 mg biw for 4 weeks. Contraindicated in deliberately immunosuppressed patients (e.g., transplant recipients) unless benefit clearly outweighs risk.
Thymosin alpha-1 (Zadaxin/thymalfasin) has one of the most substantial clinical evidence bases on the platform — 35-country approval, multiple Phase 3 trials in hepatitis B/C and cancer adjuvant indications, and a coherent TLR-mediated immune-modulation mechanism. Community/off-label use for general immune support is reasonable extrapolation from the approved indications, though no specific RCT validates the 1.0–1.5 mg biw 'wellness' protocol. Standard protocol: 1.0–1.5 mg SubQ twice weekly for 4–8 weeks. Pep IQ flags this honestly: legitimate compound with real Phase 3 evidence in approved indications, well-tolerated safety profile, but US users should source from accredited compounding pharmacies given the absence of FDA approval.
Thymosin was discovered in 1966 by Allan Goldstein and colleagues, who found a lymphocyte-stimulating factor in calf thymus. After years of isolation and purification work, Thymosin α-1 was separated from the broader thymosin fraction 5 mixture in 1977 — and found to be 10 to 1,000 times more potent than the parent mixture. It is a 28 amino acid peptide produced by thymic epithelial cells and is one of the most conserved immune-signalling molecules across mammalian species.
Its synthetic form, thymalfasin (brand name: Zadaxin), has been approved in over 35 countries and carries FDA orphan drug status for malignant melanoma, chronic active hepatitis B, DiGeorge syndrome with immune defects, and hepatocellular carcinoma. A 2024 comprehensive review covering over 30 clinical trials and more than 11,000 human subjects evaluated its safety and efficacy across COVID-19, autoimmune conditions, and cancer treatment — making it the most thoroughly human-tested immune-modulating peptide in this book.
Tα1's mechanism is unusually well-characterised for a peptide of its age — decades of research have converged on a clear picture of how it modulates immune response without crude immunosuppression or wholesale activation.
The TESTS Trial (BMJ, 2025) — the most important recent data point: The TESTS trial enrolled 1,106 sepsis patients in a randomised controlled trial of thymalfasin. The primary endpoint — 28-day mortality — was not significantly different overall. However, a pre-specified subgroup analysis showed significant benefit in patients aged 60 and over. This is not a failure of the compound but a signal about the population in which the immune restoration effect matters most: older patients whose immune systems are less capable of self-correction.
Thymosin α-1 occupies a unique position in this book: it is the immune peptide that has most successfully crossed from biohacker interest into legitimate mainstream medicine. It is prescribed by oncologists. It is approved by regulators. Its mechanism is well understood. Its safety data is extraordinary. The TESTS trial result — neutral on overall sepsis mortality, positive in elderly — does not diminish its standing; it refines the understanding of which patients benefit most.
The cancer adjunct data is the most compelling application: the HCC post-resection survival improvement (5-year OS 82.9% vs 62.9%) is a clinically meaningful outcome, not a surrogate endpoint. The immunological non-responder HIV data opens a therapeutic gap that standard ART does not address. The immunosenescence applications are the newest frontier and the most relevant to the broader anti-ageing community.
For those in countries where Zadaxin is approved: this is a medical decision with real physician support available. For those sourcing independently: the safety profile is reassuring, but the legal status and quality control question is real.